N/A N=211 TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051
Opioid Use Disorder
Primary: Days of Opioid Use — 6.8 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=665 Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
Opioid Dependence · Opioid Related Disorders
Primary: Cumulative Distribution Function (CDF) of the Percentage of Urine Samples Negative for Opioids Combined With Self-Reports Negative for Illicit Opioid Use Collected From…
N/A N=437 OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
Opioid-use Disorder
Primary: Treatment Success Rate — 70; 67 Participants — p=0.7326
N/A N=321 Subthreshold Opioid Use Disorder Prevention (STOP) Trial
Opioid-use Disorder
Primary: Days of Risky Opioid Use in Past 180 Days — 12.2; 15.5 days
N/A N=190 Opioid Prescribing After Cesarean Delivery
Surgery · Opioid Use
Primary: Unused Opioids — 5; 10 oxycodone 5mg tablets
Phase 4 N=160 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty
Joint Disease · Pain, Acute · Pain, Chronic
Primary: Opioid Use — 288; 432.5 Oral Morphine Equivalent (mg)
Phase 1 N=20 Oxytocin, Stress, Craving, Opioid Use Disorder
Opioid Use Disorder
Primary: Opioid Craving — 21.6; 22.4; 23.3; 23.4 score on a scale
Phase 1 N=27 Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder
Opioid Abuse · Opioid Dependence · Opioid-Related Disorders
Primary: Change in Subjective Response to Oxycodone Measured With 100 Millimeter Visual Analog Scale — -13.81; -9.67 units on a scale
N/A N=200 Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes
Opioid-use Disorder · Medication Assisted Treatment · Chronic Pain
Primary: Retention on Buprenorphine Treatment According to TimeLine Follow-Back - 3-months — 81.1; 75.4 days
N/A N=1,731 Opioid Use Disorder in the Emergency Department: CTN 0069
Opioid Use Disorder
Primary: Implementation (Considered the Primary Outcome) — 2; 53 Participants — p=<0.001
N/A N=395 Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder
Opiate Antagonist Overdose · Opioid-Related Disorders
Primary: To Measure the Association of Take-home Naloxone With Overdose Reversals Performed by Patients With Opioid Use Disorder Enrolled in an Opioid Treatment Program — 73; 263…
N/A N=1,542 Emergency Department Outcomes for Patients With Opioid Use Disorder
Opioid-use Disorder
Primary: Percent of Participants Who Received Emergency Department (ED)-Initiated/Expedited Buprenorphine (BUP) — 39.40 Percentage of participants
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
Phase 2 N=13 Suvorexant for Opioid/Stimulant Co-use
Opioid Use Disorder · Stimulant Use Disorder
Primary: Opioid Use: Proportion of Positive Urine Drug Screens (UDS) — 0.83; 0.67 Proportion of urine drug screens
N/A N=119 Stress Response in Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale
Phase 3 N=49 Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
Opioid-use Disorder
Primary: Proportion of Patients Successfully Inducted to Receive Naltrexone Injection — 12; 7 Participants
Phase 3 N=20 Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders
Substance-Related Disorders · Substance Use Disorders · Substance Abuse, Intravenous
Primary: Opioid Craving Using Visual Analogue Scale — 3.909; 6; 4.556; 5.5 score on a scale
N/A N=55 Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR
Opioid-use Disorder
Primary: Intervention PCP Confidence in Assessing and Treating OUD — 6; 11; 8; 1 Participants
Phase 2 N=12 Oxytocin Treatment of Opioid Dependence
Opioid Dependence · Opioid Withdrawal
Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours
N/A N=213 Single Session Class to Reduce Opioid Use in Chronic Pain
Chronic Pain
Primary: Opioid Use — -6.7; -8.0 MME — p=.89
Phase 2 N=15 Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Cue-reactivity — 0.7; 1.1; 0.9; 2.4 score on a scale
Phase 2 N=10 An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder
Opioid-use Disorder
Primary: Sublocade Induction — 10 Participants
N/A N=104 Start Treatment and Recovery for Opioid Use Disorder
Opioid-use Disorder · Mental Disorder · Opioid Medication Assisted Treatment
Primary: Number of Participants With Self-reported Treatment Retention — 51 Participants
N/A N=240 Opioid Use After Thyroid and Parathyroid Surgeries
Thyroidectomy · Parathyroidectomy · Opioid Use
Primary: New Opioid Discharge Prescriptions — 128; 28 Participants
Phase 2 N=47 A Multiple Dose Opioid Challenge Study
Moderate or Severe Opioid Use Disorder
Primary: Treatment Phase Drug Liking Visual Analog Scale (VAS) Emax Scores for Baseline and Four Challenge Sessions Compared to Baseline (Completer Population) for CAM2038 q1w…
Phase 2 N=27 Prescription Opioid Effects in Abusers Versus Non-Abusers
Opioid-Related Disorders · Substance-Related Disorders
Primary: Breakpoint — 25; 400; 1400; 850 Mouse Clicks
Phase 2 N=30 Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder
Opioid-use Disorder
Primary: The Primary Endpoint Will be Safety and Tolerability of CBD. — 13; 4 participants
N/A N=19 mHealth for Patient Self-Management of Opioid Use Disorder
Opioid-use Disorder
Primary: Usability Score — 89.5 score on a scale
Early Phase 1 N=7 Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine
Addiction
Primary: Agitation Calmness Evaluation Scale (ACES) — 4; 4; 4; 4.07 score on a scale
N/A N=112 Co-Use of Opioid Medications and Alcohol Prevention Study
Alcohol Drinking · Opioid Use
Primary: Alcohol Use Reductions — 11; 12; 1; 1 Participants